

## Jaypirca® (pirtobrutinib) - New indication

- On December 1, 2023, <u>Eli Lilly announced</u> the FDA approval of <u>Jaypirca (pirtobrutinib)</u>, for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
  - This indication is approved under accelerated approval based on response rate.
    Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Jaypirca is also approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
- The approval of Jaypirca for the new indication was based on BRUIN, an open-label, single-arm, multicohort study in patients with CLL/SLL. Efficacy was based on 108 patients with CLL/SLL treated with Jaypirca who were previously treated with at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. Efficacy was established based on overall response rate (ORR) and duration of response (DOR).
  - The ORR was 72% (95% CI: 63, 80).
  - The median DOR was 12.2 months (95% CI: 9.3, 14.7).
- The recommended dose of Jaypirca for both MCL and CLL/SLL is 200 mg orally once daily until disease progression or unacceptable toxicity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.